Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

The treatment of multiple sclerosis has been transformed by the successful development of
immunotherapies that efficiently reduce disease activity and related clinical relapses during …

Oligodendrocytes generate multiple layers of myelin membrane around axons of the central
nervous system to enable fast and efficient nerve conduction. Until recently, saltatory nerve …

Oligodendrocyte pathology is increasingly implicated in neurodegenerative diseases as
oligodendrocytes both myelinate and provide metabolic support to axons. In multiple …

Cognitive decline is recognized as a prevalent and debilitating symptom of multiple sclerosis
(MS), especially deficits in episodic memory and processing speed. The field aims to (1) …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …

Although the core concept of remyelination—based on the activation, migration, proliferation
and differentiation of CNS progenitors—has not changed over the past 20 years, our …

Despite the large number of immunomodulatory or immunosuppressive treatments available
to treat relapsing–remitting multiple sclerosis (MS), treatment of the progressive phase of the …

In multiple sclerosis, an inflammatory attack results in myelin loss, which can be partially
reversed by remyelination. Recent studies suggest that mature oligodendrocytes could …

Multiple sclerosis is characterized by inflammatory activity that results in destruction of the
myelin sheaths that enwrap axons. The currently available medications for multiple sclerosis …